Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $161,000.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $16.10, for a total transaction of $161,000.00. Following the transaction, the insider now directly owns 1,057,535 shares in the company, valued at $17,026,313.50. The trade was a 0.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $14.32 on Friday. The stock’s 50 day moving average price is $14.44 and its 200 day moving average price is $14.41. Day One Biopharmaceuticals, Inc. has a 12 month low of $11.30 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter last year, the company earned ($0.54) EPS. Research analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several large investors have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its stake in shares of Day One Biopharmaceuticals by 19.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock worth $33,575,000 after acquiring an additional 336,281 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Day One Biopharmaceuticals by 517.0% during the second quarter. AQR Capital Management LLC now owns 113,020 shares of the company’s stock valued at $1,557,000 after purchasing an additional 94,703 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Day One Biopharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after purchasing an additional 1,447 shares during the period. TimesSquare Capital Management LLC boosted its position in shares of Day One Biopharmaceuticals by 8.2% in the 3rd quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company’s stock valued at $25,460,000 after purchasing an additional 139,160 shares during the period. Finally, Deerfield Management Company L.P. Series C boosted its position in shares of Day One Biopharmaceuticals by 65.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock valued at $40,281,000 after purchasing an additional 1,157,825 shares during the period. Institutional investors own 87.95% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on DAWN. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Bank of America raised Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price target for the company from $11.00 to $24.00 in a report on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.